Surgery pp 841-874 | Cite as

Stomach and Duodenum

  • Robert E. Glasgow
  • Michael D. Rollins


The stomach is a J-shaped dilation of the alimentary tract derived from the embryonic foregut. It lies in the left upper quadrant of the abdomen where the gastroesophageal junction is located to the left of the 10th thoracic vertebrae and crosses the midline at the pylorus, which is to the right of the LI vertebral body. It is contiguous proximally with the esophagus and distally with the duodenum (Fig. 45.1). The stomach is fixed in two locations, the gastroesophageal junction and the retroperitoneal attachments at the duodenum. It can be divided into four anatomic regions (Fig. 45.2). The cardia is the most proximal region and is located just distal and to the left of the gastroesophageal junction. The fundus projects upward and is in contact with the left hemidiaphragm to the right of the spleen. The corpus, or body, is the largest portion of the stomach and is located below the fundus. The most distal portion of the stomach is the antrum. Its proximal boundary is an arbitrary line connecting the incisura angularis, which is located approximately two-thirds of the distance down the lesser curvature, to the greater curvature where the gastroepiploic arteries enter the stomach.


Gastric Cancer Peptic Ulcer Duodenal Ulcer Gastric Ulcer Pylorus Infection 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hildebrand P, Lehmann FS, Ketterer S, et al. Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist. Gut 2001;49:23–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Debas HT, Mulvihill SJ. Neuroendocrine design of the gut. Am J Surg 1991;161:243–249.PubMedCrossRefGoogle Scholar
  3. 3.
    Pappas TN, Debas HT, Taylor IL. Enterogastrone-like effect of peptide YY is vagally mediated in the dog. J Clin Invest 1986;77:49–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Sonnenberg A. The US temporal and geographic variations of diseases related to Helicobacter pylori. Am J Public Health 1993;83:1006–1010.PubMedCrossRefGoogle Scholar
  5. 5.
    Fowler SF, Khoubian JF, Mathiasen RA, Margulies DR. Peptic ulcers in the elderly is a surgical disease. Am J Surg 2001;182:733–737.PubMedCrossRefGoogle Scholar
  6. 6.
    Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(suppl 2):59–69.PubMedGoogle Scholar
  7. 7.
    Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995;9(suppl 2):33–39.PubMedGoogle Scholar
  8. 8.
    Feil W, Klimesch S, Karner P, et al. Importance of an alkaline microenvironment for rapid restitution of the rabbit duodenal mucosa in vitro. Gastroenterology 1989;97:112–122.PubMedGoogle Scholar
  9. 9.
    Barnard JA, Beauchamp RD, Russell WE, et al. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995;108:564–580.PubMedCrossRefGoogle Scholar
  10. 10.
    Isenberg JI, Selling JA, Hogan DL, Koss MA. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med 1987;316:374–379.PubMedGoogle Scholar
  11. 11.
    Hogan DL, Rapier RC, Dreilinger A, et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology 1996;110:705–716.PubMedCrossRefGoogle Scholar
  12. 12.
    Fandriks L, von Bothmer C, Johansson B, et al. Water extract of Helicobacter pylori inhibits duodenal mucosal alkaline secretion in anesthetized rats. Gastroenterology 1997;113:1570–1575.PubMedCrossRefGoogle Scholar
  13. 13.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–1315.PubMedCrossRefGoogle Scholar
  14. 14.
    Parsonnet J. Helicobacter pylori: the size of the problem. Gut 1998;43(suppl 1):S6–S9.PubMedGoogle Scholar
  15. 15.
    Covacci A, Telford JL, Del Giudice G, et al. Helicobacter pylori virulence and genetic geography. Science 1999;284:1328–1333.PubMedCrossRefGoogle Scholar
  16. 16.
    Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995;9(suppl 2):45–51.PubMedGoogle Scholar
  17. 17.
    Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000;54:615–640.PubMedCrossRefGoogle Scholar
  18. 18.
    Moss SF, Calam J, Agarwal B, et al. Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996;38:498–501.PubMedCrossRefGoogle Scholar
  19. 19.
    Passaro DJ, Chosy EJ, Parsonnet J. Helicobacter pylori: consensus and controversy. Clin Infect Dis 2002;35:298–304.PubMedCrossRefGoogle Scholar
  20. 20.
    Israel DA, Peek RM. Pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther 2001;15:1271–1290.PubMedCrossRefGoogle Scholar
  21. 21.
    Suzuki M, Miura S, Suematsu M, et al. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am J Physiol 1992;263(5 pt 1):G719–G725.PubMedGoogle Scholar
  22. 22.
    Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992;267:10570–10575.PubMedGoogle Scholar
  23. 23.
    Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993;90:5791–5795.PubMedCrossRefGoogle Scholar
  24. 24.
    Censini S, Lange C, Xiang Z, et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996;93:14648–14653.PubMedCrossRefGoogle Scholar
  25. 25.
    Yamaoka Y, Kita M, Kodama T, et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996;110:1744–1752.PubMedCrossRefGoogle Scholar
  26. 26.
    Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002;360:933–941.PubMedCrossRefGoogle Scholar
  27. 27.
    Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2–17.PubMedCrossRefGoogle Scholar
  28. 28.
    Ma L, Chow JY, Cho CH. Cigarette smoking delays ulcer healing: role of constitutive nitric oxide synthase in rat stomach. Am J Physiol 1999;276(1 pt 1):G238–G248.PubMedGoogle Scholar
  29. 29.
    Ma L, Wang WP, Chow JY, et al. The role of poly amines in gastric mucus synthesis inhibited by cigarette smoke or its extract. Gut 2000;47:170–177.PubMedCrossRefGoogle Scholar
  30. 30.
    Cryer B, Faust TW, Goldschmiedt M, et al. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including Helicobacter pylori. Am J Gastroenterol 1992;87:1747–1754.PubMedGoogle Scholar
  31. 31.
    Konturek SJ, Bielanski W, Plonka M, et al. Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers. Scand J Gastroenterol 2003;38:923–930.PubMedCrossRefGoogle Scholar
  32. 32.
    Bardhan KD, Graham DY, Hunt RH, O’Morain CA. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997;2:27–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Chan FK, Sung JJ, Lee YT, et al. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?. Am J Gastroenterol 1997;92:442–445.PubMedGoogle Scholar
  34. 34.
    Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000;132:134–143.PubMedGoogle Scholar
  35. 35.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–1528.PubMedCrossRefGoogle Scholar
  36. 36.
    Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681–1690.PubMedCrossRefGoogle Scholar
  37. 37.
    Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016–1021.PubMedCrossRefGoogle Scholar
  38. 38.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–1255.PubMedCrossRefGoogle Scholar
  39. 39.
    McDonald MP, Broughan TA, Hermann RE, et al. Operations for gastric ulcer: a long-term study. Am Surg 1996;62:673–677.PubMedGoogle Scholar
  40. 40.
    Csendes A, Braghetto I, Smok G. Type IV gastric ulcer: a new hypothesis. Surgery 1987;101:361–366.PubMedGoogle Scholar
  41. 41.
    Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med 2002;30(6 suppl):S351–S355.PubMedCrossRefGoogle Scholar
  42. 42.
    Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999;27:2812–2817.PubMedCrossRefGoogle Scholar
  43. 43.
    Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377–381.PubMedCrossRefGoogle Scholar
  44. 44.
    Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996;275:308–314.PubMedCrossRefGoogle Scholar
  45. 45.
    Weeks DL, Eskandari S, Scott DR, Sachs G. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science 2000;287:482–485.PubMedCrossRefGoogle Scholar
  46. 46.
    Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies. Am J Clin Pathol 2003;119:403–412.PubMedCrossRefGoogle Scholar
  47. 47.
    Monteiro L, de Mascarel A, Sarrasqueta AM, et al. Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol 2001;96:353–358.PubMedCrossRefGoogle Scholar
  48. 48.
    Dore MP, Negrini R, Tadeu V, et al. Novel monoclonal antibody-based Helicobacter pylori stool antigen test. Helicobacter 2004;9:228–232.PubMedCrossRefGoogle Scholar
  49. 49.
    Laheij RJ, Straatman H, Jansen JB, Verbeek AL. Evaluation of commercially available Helicobacter pylori serology kits: a review. J Clin Microbiol 1998;36:2803–2809.PubMedGoogle Scholar
  50. 50.
    Faigel DO, Magaret N, Corless C, et al. Evaluation of rapid antibody tests for the diagnosis of Helicobacter pylori infection. Am J Gastroenterol 2000;95:72–77.PubMedCrossRefGoogle Scholar
  51. 51.
    Cutler AF, Havstad S, Ma CK, et al. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995;109:136–141.PubMedCrossRefGoogle Scholar
  52. 52.
    Levine MS, Rubesin SE. The Helicobacter pylori revolution: radiologic perspective. Radiology 1995;195:593–596.PubMedGoogle Scholar
  53. 53.
    Spechler SJ. Peptic ulcer disease and its complications. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Vol. 1. Philadelphia: Saunders; 2002:747–781.Google Scholar
  54. 54.
    Grossman MI. The Veterans Administration Cooperative Study on Gastric Ulcer. 10. Resume and comment. Gastroenterology 1971;61(suppl 2):635–638.PubMedGoogle Scholar
  55. 55.
    Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2330–2338.PubMedCrossRefGoogle Scholar
  56. 56.
    Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217–1220.PubMedCrossRefGoogle Scholar
  57. 57.
    Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118(2 suppl 1):S9–S31.PubMedCrossRefGoogle Scholar
  58. 58.
    Holt S, Howden CW. Omeprazole. Overview and opinion. Dig Dis Sci 1991;36:385–393.PubMedCrossRefGoogle Scholar
  59. 59.
    Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995;7:661–665.PubMedGoogle Scholar
  60. 60.
    Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole versus ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455–1461.PubMedCrossRefGoogle Scholar
  61. 61.
    Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719–726.PubMedCrossRefGoogle Scholar
  62. 62.
    Malfertheiner P, Kirchner T, Kist M, et al. Helicobacter pylori eradication and gastric ulcer healing—comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 2003;17:1125–1135.PubMedCrossRefGoogle Scholar
  63. 63.
    Ruiz B, Correa P, Fontham ET, Ramakrishnan T. Antral atrophy, Helicobacter pylori colonization, and gastric pH. Am J Clin Pathol 1996;105:96–101.PubMedGoogle Scholar
  64. 64.
    Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139–142.PubMedCrossRefGoogle Scholar
  65. 65.
    Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori?. A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003;17:111–117.PubMedCrossRefGoogle Scholar
  66. 66.
    Campbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002;97:2208–2214.PubMedCrossRefGoogle Scholar
  67. 67.
    Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345–351.PubMedGoogle Scholar
  68. 68.
    Maton PN. Omeprazole. N Engl J Med 1991;324:965–975.PubMedGoogle Scholar
  69. 69.
    Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834–1840.PubMedCrossRefGoogle Scholar
  70. 70.
    Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244–1252.PubMedCrossRefGoogle Scholar
  71. 71.
    Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998;93:1409–1415.PubMedGoogle Scholar
  72. 72.
    Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437–1442.PubMedCrossRefGoogle Scholar
  73. 73.
    Sonnenberg A, Olson CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999;94:950–954.PubMedCrossRefGoogle Scholar
  74. 74.
    Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 2002;136:13–24.PubMedGoogle Scholar
  75. 75.
    Laine L. Is it time for quadruple therapy to be first line? Can J Gastroenterol 2003;17(suppl B):33B–35B.PubMedGoogle Scholar
  76. 76.
    Perri F, Festa V, Merla A, et al. Randomized study of different “second-line” therapies for Helicobacter pylori infection after failure of the standard “Maastricht triple therapy.” Aliment Pharmacol Ther 2003;18:815–820.PubMedCrossRefGoogle Scholar
  77. 77.
    Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833–1855.PubMedCrossRefGoogle Scholar
  78. 78.
    Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002;97:2950–2961.PubMedCrossRefGoogle Scholar
  79. 79.
    Millat B, Fingerhut A, Borie F. Surgical treatment of complicated duodenal ulcers: controlled trials. World J Surg 2000;24:299–306.PubMedCrossRefGoogle Scholar
  80. 80.
    Goligher JC, Pulvertaft CN, De Dombal FT, et al. Clinical comparison of vagotomy and pyloroplasty with other forms of elective surgery for duodenal ulcer. Br Med J 1968;2:787–789.PubMedCrossRefGoogle Scholar
  81. 81.
    Goligher JC, Pulvertaft CN, De Dombal FT, et al. Five to eight-year results of Leeds-York controlled trial of elective surgery for duodenal ulcer. Br Med J 1968;2:781–787.PubMedCrossRefGoogle Scholar
  82. 82.
    Goligher JC, Pulvertaft CN, Irvin TT, et al. Five-to eight-year results of truncal vagotomy and pyloroplasty for duodenal ulcer. Br Med J 1972;1:7–13.PubMedCrossRefGoogle Scholar
  83. 83.
    Jordan PH Jr, Condon RE. A prospective evaluation of vagotomypyloroplasty and vagotomy-antrectomy for treatment of duodenal ulcer. Ann Surg 1970;172:547–563.PubMedCrossRefGoogle Scholar
  84. 84.
    Price WE, Grizzle JE, Postlethwait RW, et al. Results of operation for duodenal ulcer. Surg Gynecol Obstet 1970;131:233–244.PubMedGoogle Scholar
  85. 85.
    Hoffmann J, Jensen HE, Christiansen J, et al. Prospective controlled vagotomy trial for duodenal ulcer. Results after 11–15 years. Ann Surg 1989;209:40–45.PubMedCrossRefGoogle Scholar
  86. 86.
    Jordan PH Jr, Thornby J. Twenty years after parietal cell vagotomy or selective vagotomy antrectomy for treatment of duodenal ulcer. Final report. Ann Surg 1994;220:283–293; discussion 293–296.PubMedCrossRefGoogle Scholar
  87. 87.
    Macintyre IM, Millar A, Smith AN, Small WP. Highly selective vagotomy 5–15 years on. Br J Surg 1990;77:65–69.PubMedCrossRefGoogle Scholar
  88. 88.
    Meisner S, Hoffmann J, Jensen HE. Parietal cell vagotomy. A 23-year study. Ann Surg 1994;220:164–167.PubMedCrossRefGoogle Scholar
  89. 89.
    Mulholland MW, Debas HT. Chronic duodenal and gastric ulcer. Surg Clin North Am 1987;67:489–507.PubMedGoogle Scholar
  90. 90.
    Taylor TV, Lythgoe JP, McFarland JB, et al. Anterior lesser curve seromyotomy and posterior truncal vagotomy versus truncal vagotomy and pyloroplasty in the treatment of chronic duodenal ulcer. Br J Surg 1990;77:1007–1009.PubMedCrossRefGoogle Scholar
  91. 91.
    Walia HS, Abd el-Karim HA. Anterior lesser curve seromyotomy with posterior truncal vagotomy versus proximal gastric vagotomy: results of a prospective randomized trial 3-8 years after surgery. World J Surg 1994;18:758–763.PubMedCrossRefGoogle Scholar
  92. 92.
    Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998;338:791–797.PubMedCrossRefGoogle Scholar
  93. 93.
    Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997,42:1255–1259.Google Scholar
  94. 94.
    Spirt MJ. Acid suppression in critically ill patients: what does the evidence support? Pharmacotherapy 2003;23(10 pt 2):87S–93S.PubMedCrossRefGoogle Scholar
  95. 95.
    Labenz J, Peitz U, Leusing C, et al. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997;40:36–41.PubMedGoogle Scholar
  96. 96.
    Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310–316.PubMedCrossRefGoogle Scholar
  97. 97.
    Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72h. Am J Gastroenterol 1999;94:351–357.PubMedGoogle Scholar
  98. 98.
    Walt RP, Cottrell J, Mann SG, et al. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992;340:1058–1062.PubMedCrossRefGoogle Scholar
  99. 99.
    Zuckerman G, Welch R, Douglas A, et al. Controlled trial of medical therapy for active upper gastrointestinal bleeding and prevention of rebleeding. Am J Med 1984;76:361–366.PubMedCrossRefGoogle Scholar
  100. 100.
    Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001;111:280–284.PubMedCrossRefGoogle Scholar
  101. 101.
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037–2046.PubMedCrossRefGoogle Scholar
  102. 102.
    Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948.PubMedCrossRefGoogle Scholar
  103. 103.
    Jacobsen RB, Phillips BB. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs. Ann Pharmacother 2004;38:1469–1481.PubMedCrossRefGoogle Scholar
  104. 104.
    Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31:753–758.PubMedCrossRefGoogle Scholar
  105. 105.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–249.PubMedGoogle Scholar
  106. 106.
    Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998;12:135–140.PubMedCrossRefGoogle Scholar
  107. 107.
    Shaffer HA Jr. Perforation and obstruction of the gastrointestinal tract. Assessment by conventional radiology. Radiol Clin North Am 1992;30:405–426.PubMedGoogle Scholar
  108. 108.
    Gunshefski L, Flancbaum L, Brolin RE, Frankel A. Changing patterns in perforated peptic ulcer disease. Am Surg 1990;56:270–274.PubMedGoogle Scholar
  109. 109.
    Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683–689.PubMedCrossRefGoogle Scholar
  110. 110.
    Svanes C. Trends in perforated peptic ulcer: incidence, etiology, treatment, and prognosis. World J Surg 2000;24:277–283.PubMedCrossRefGoogle Scholar
  111. 111.
    Datsis AC, Rogdakis A, Kekelos S, et al. Simple closure of chronic duodenal ulcer perforation in the era of Helicobacter pylori: an old procedure, today’s solution. Hepatogastroenterology 2003;50:1396–1398.PubMedGoogle Scholar
  112. 112.
    Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000;231:153–158.PubMedCrossRefGoogle Scholar
  113. 113.
    Boey J, Choi SK, Poon A, Alagaratnam TT. Risk stratification in perforated duodenal ulcers. A prospective validation of predictive factors. Ann Surg 1987;205:22–26.PubMedCrossRefGoogle Scholar
  114. 114.
    Hay JM, Lacaine F, Kohlmann G, Fingerhut A. Immediate definitive surgery for perforated duodenal ulcer does not increase operative mortality: a prospective controlled trial. World J Surg 1988;12:705–709.PubMedCrossRefGoogle Scholar
  115. 115.
    Tanphiphat C, Tanprayoon T, Na Thalang A. Surgical treatment of perforated duodenal ulcer: a prospective trial between simple closure and definitive surgery. Br J Surg 1985,72:370–372.Google Scholar
  116. 116.
    Gisbert JP, Pajares JM. Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter 2003;8:159–167.PubMedCrossRefGoogle Scholar
  117. 117.
    Alamowitch B, Aouad K, Sellam P, et al. [Laparoscopic treatment of perforated duodenal ulcer]. Gastroenterol Clin Biol 2000;24:1012–1017.PubMedGoogle Scholar
  118. 118.
    Metzger J, Styger S, Sieber C, et al. Prevalence of Helicobacter pylori infection in peptic ulcer perforations. Swiss Med Wkly 2001;131:99–103.PubMedGoogle Scholar
  119. 119.
    Tran TT, Quandalle P. [Treatment of perforated gastroduodenal ulcer by simple suture followed by Helicobacter pylori eradication]. Ann Chir 2002;127:32–34.PubMedCrossRefGoogle Scholar
  120. 120.
    Blomgren LG. Perforated peptic ulcer: long-term results after simple closure in the elderly. World J Surg 1997;21:412–414; discussion 414–415.PubMedCrossRefGoogle Scholar
  121. 121.
    Irvin TT. Mortality and perforated peptic ulcer: a case for risk stratification in elderly patients. Br J Surg 1989;76:215–218.PubMedCrossRefGoogle Scholar
  122. 122.
    Lau WY, Leung KL, Zhu XL, et al. Laparoscopic repair of perforated peptic ulcer. Br J Surg 1995;82:814–816.PubMedCrossRefGoogle Scholar
  123. 123.
    Hodnett RM, Gonzalez F, Lee WC, et al. The need for definitive therapy in the management of perforated gastric ulcers. Review of 202 cases. Ann Surg 1989;209:36–39.PubMedCrossRefGoogle Scholar
  124. 124.
    Jordan PH Jr. Surgery for peptic ulcer disease. Curr Probl Surg 1991;28:265–330.PubMedCrossRefGoogle Scholar
  125. 125.
    Herrington JL Jr, Sawyers JL. Gastric ulcer. Curr Probl Surg 1987;24:759–865.PubMedCrossRefGoogle Scholar
  126. 126.
    Robles R, Parrilla P, Lujan JA, et al. Long-term follow-up of bilateral truncal vagotomy and pyloroplasty for perforated duodenal ulcer. Br J Surg 1995;82:665.PubMedCrossRefGoogle Scholar
  127. 127.
    Siu WT, Leong HT, Law BK, et al. Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial. Ann Surg 2002;235:313–319.PubMedCrossRefGoogle Scholar
  128. 128.
    Mondardini A, Barletti C, Rocca G, et al. Non-variceal upper gastrointestinal bleeding and Forrest’s classification: diagnostic agreement between endoscopists from the same area. Endoscopy 1998;30:508–512.PubMedCrossRefGoogle Scholar
  129. 129.
    Silverstein FE, Gilbert DA, Tedesco FJ, et al. The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Gastrointest Endosc 1981;27:80–93.PubMedCrossRefGoogle Scholar
  130. 130.
    Allan R, Dykes P. A study of the factors influencing mortality rates from gastrointestinal haemorrhage. Q J Med 1976;45:533–550.PubMedGoogle Scholar
  131. 131.
    Clason AE, Macleod DA, Elton RA. Clinical factors in the prediction of further haemorrhage or mortality in acute upper gastrointestinal haemorrhage. Br J Surg 1986;73:985–987.PubMedCrossRefGoogle Scholar
  132. 132.
    Kankaria AG, Fleischer DE. The critical care management of nonvariceal upper gastrointestinal bleeding. Crit Care Clin 1995;11:347–368.PubMedGoogle Scholar
  133. 133.
    Van Dam J, Brugge WR. Endoscopy of the upper gastrointestinal tract. N Engl J Med 1999;341:1738–1748.PubMedCrossRefGoogle Scholar
  134. 134.
    Savides TJ, Jensen DM. Therapeutic endoscopy for nonvariceal gastrointestinal bleeding. Gastroenterol Clin North Am 2000;29:465–487, vii.PubMedCrossRefGoogle Scholar
  135. 135.
    Machicado GA, Jensen DM. Thermal probes alone or with epinephrine for the endoscopic haemostasis of ulcer haemorrhage. Baillieres Best Pract Res Clin Gastroenterol 2000;14:443–458.PubMedCrossRefGoogle Scholar
  136. 136.
    Calvet X, Vergara M, Brullet E, et al. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology 2004;126:441–450.PubMedCrossRefGoogle Scholar
  137. 137.
    Sung JJ, Chan FK, Lau JY, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with non-bleeding visible vessels or adherent clots: a randomized comparison. Ann Intern Med 2003;139:237–243.PubMedGoogle Scholar
  138. 138.
    Gisbert JP, Khorrami S, Carballo F, et al. Meta-analysis: Helicobacter pylori eradication therapy versus antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;19:617–629.PubMedCrossRefGoogle Scholar
  139. 139.
    Lau JY, Sung JJ, Lam YH, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999;340:751–756.PubMedCrossRefGoogle Scholar
  140. 140.
    Shope TR, Kauffman GL Jr. Duodenal ulcer. In: Cameron JL, ed. Current Surgical Therapy. Philadelphia: Elsevier Mosby; 2004:71–76.Google Scholar
  141. 141.
    Millat B, Hay JM, Valleur P, et al. Emergency surgical treatment for bleeding duodenal ulcer: oversewing plus vagotomy versus gastric resection, a controlled randomized trial. French Associations for Surgical Research. World J Surg 1993;17:568–573; discussion 574.PubMedCrossRefGoogle Scholar
  142. 142.
    Sirinek KR, Bingener J, Richards ML. Benign gastric ulcer and stress gastritis. In: Cameron JL, ed. Current Surgical Therapy. Philadelphia: Elsevier Mosby; 2004:67–70.Google Scholar
  143. 143.
    Weiland D, Dunn DH, Humphrey EW, Schwartz ML. Gastric outlet obstruction in peptic ulcer disease: an indication for surgery. Am J Surg 1982;143:90–93.PubMedCrossRefGoogle Scholar
  144. 144.
    Choudhary AM, Roberts I, Nagar A, et al. Helicobacter pylori-related gastric outlet obstruction: is there a role for medical treatment? J Clin Gastroenterol 2001;32:272–273.PubMedCrossRefGoogle Scholar
  145. 145.
    Gisbert JP, Pajares JM. Review article: Helicobacter pylori infection and gastric outlet obstruction—prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther 2002;16:1203–1208.PubMedCrossRefGoogle Scholar
  146. 146.
    Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995;90:1769–1770.PubMedGoogle Scholar
  147. 147.
    Boylan JJ, Gradzka MI. Long-term results of endoscopic balloon dilatation for gastric outlet obstruction. Dig Dis Sci 1999;44:1883–1886.PubMedCrossRefGoogle Scholar
  148. 148.
    Gibson JB, Behrman SW, Fabian TC, Britt LG. Gastric outlet obstruction resulting from peptic ulcer disease requiring surgical intervention is infrequently associated with Helicobacter pylori infection. J Am Coll Surg 2000;191:32–37.PubMedCrossRefGoogle Scholar
  149. 149.
    Kate V, Ananthakrishnan N, Badrinath S, et al. Helicobacter pylori infection in duodenal ulcer with gastric outlet obstruction. Trop Gastroenterol 1998;19:75–77.PubMedGoogle Scholar
  150. 150.
    Taskin V, Gurer I, Ozyilkan E, et al. Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction. Helicobacter 2000;5:38–40.PubMedCrossRefGoogle Scholar
  151. 151.
    de Boer WA, Driessen WM. Resolution of gastric outlet obstruction after eradication of Helicobacter pylori. J Clin Gastroenterol 1995;21:329–330.PubMedCrossRefGoogle Scholar
  152. 152.
    Malik GM, Romshoo GHJ, Basu JA. Helicobacter pylori and gastric outlet obstruction. Am J Gastroenterol 1998;93:2004.PubMedCrossRefGoogle Scholar
  153. 153.
    Solt J, Bajor J, Szabo M, Horvath OP. Long-term results of balloon catheter dilation for benign gastric outlet stenosis. Endoscopy 2003;35:490–495.PubMedCrossRefGoogle Scholar
  154. 154.
    DiSario JA, Fennerty MB, Tietze CC, et al. Endoscopic balloon dilation for ulcer-induced gastric outlet obstruction. Am J Gastroenterol 1994;89:868–871.PubMedGoogle Scholar
  155. 155.
    Zittel TT, Jehle EC, Becker HD. Surgical management of peptic ulcer disease today—indication, technique and outcome. Langenbecks Arch Surg 2000;385:84–96.PubMedCrossRefGoogle Scholar
  156. 156.
    Csendes A, Maluenda F, Braghetto I, et al. Prospective randomized study comparing three surgical techniques for the treatment of gastric outlet obstruction secondary to duodenal ulcer. Am J Surg 1993;166:45–49.PubMedCrossRefGoogle Scholar
  157. 157.
    Horn S, Sarr MG, Kelly KA, Hench V. Postoperative gastric atony after vagotomy for obstructing peptic ulcer. Am J Surg 1989;157:282–286.CrossRefGoogle Scholar
  158. 158.
    McCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Long-term follow-up with subjective and objective parameters. Dig Dis Sci 1991;36:1556–1561.PubMedCrossRefGoogle Scholar
  159. 159.
    Wyman A, Stuart RC, Ng EK, et al. Laparoscopic truncal vagotomy and gastroenterostomy for pyloric stenosis. Am J Surg 1996;171:600–603.PubMedCrossRefGoogle Scholar
  160. 160.
    Glasgow RE, Mulvihill SJ. Postgastrectomy syndromes. Probl Gen Surg 1997;14:132–152.Google Scholar
  161. 161.
    Cheadle WG, Baker PR, Cuschieri A. Pyloric reconstruction for severe vasomotor dumping after vagotomy and pyloroplasty. Ann Surg 1985;202:568–572.PubMedGoogle Scholar
  162. 162.
    Vogel SB, Hocking MP, Woodward ER. Clinical and radionuclide evaluation of Roux-en-Y diversion for postgastrectomy dumping. Am J Surg 1988;155:57–62.PubMedCrossRefGoogle Scholar
  163. 163.
    Sawyers JL, Herrington JL Jr, Buckspan GS. Remedial operation for alkaline reflux gastritis and associated postgastrectomy syndromes. Arch Surg 1980;115:519–524.PubMedGoogle Scholar
  164. 164.
    Cuschieri A. Surgical management of severe intractable postva-gotomy diarrhoea. Br J Surg 1986;73:981–984.PubMedCrossRefGoogle Scholar
  165. 165.
    Zobolas B, Sakorafas GH, Kouroukli I, et al. Alkaline reflux gastritis: early and late results of surgery. World J Surg 2006;30:1043–1049.PubMedCrossRefGoogle Scholar
  166. 166.
    Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998;102–103:227–234.PubMedCrossRefGoogle Scholar
  167. 167.
    SEER Cancer Statistics Review 1975–2001. National Cancer Institute; 2004. Available at: Scholar
  168. 168.
    Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583–592.PubMedCrossRefGoogle Scholar
  169. 169.
    Locke GR 3rd, Talley NJ, Carpenter HA, et al. Changes in the site-and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology 1995;109:1750–1756.PubMedCrossRefGoogle Scholar
  170. 170.
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–6740.PubMedGoogle Scholar
  171. 171.
    Houghton J, Wang TC. Tumors of the stomach. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Vol. 1. Philadelphia: Saunders; 2006:1139–1170.Google Scholar
  172. 172.
    Toftgaard C. Gastric cancer after peptic ulcer surgery. A historic prospective cohort investigation. Ann Surg 1989;210:159–164.PubMedCrossRefGoogle Scholar
  173. 173.
    Schuman BM, Waldbaum JR, Hiltz SW. Carcinoma of the gastric remnant in a US population. Gastrointest Endosc 1984;30:71–73.PubMedCrossRefGoogle Scholar
  174. 174.
    Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006;191:134–138.PubMedCrossRefGoogle Scholar
  175. 175.
    Yano M, Tsujinaka T, Shiozaki H, et al. Appraisal of treatment strategy by staging laparoscopy for locally advanced gastric cancer. World J Surg 2000;24:1130–1135; discussion 1135–1136.PubMedCrossRefGoogle Scholar
  176. 176.
    Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005;12:347–353.PubMedCrossRefGoogle Scholar
  177. 177.
    Shiu MH, Moore E, Sanders M, et al. Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis. Arch Surg 1987;122:1347–1351.PubMedGoogle Scholar
  178. 178.
    Wanebo HJ, Kennedy BJ, Winchester DP, et al. Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. J Am Coll Surg 1997;185:177–184.PubMedGoogle Scholar
  179. 179.
    Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559–563.PubMedCrossRefGoogle Scholar
  180. 180.
    Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908–914.PubMedCrossRefGoogle Scholar
  181. 181.
    Pacelli F, Sgadari A, Doglietto GB. Surgery for gastric cancer. N Engl J Med 1999;341:538–539.PubMedCrossRefGoogle Scholar
  182. 182.
    Bunt AM, Hermans J, Smit VT, et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995;13:19–25.PubMedGoogle Scholar
  183. 183.
    Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after Dl and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995–999.PubMedCrossRefGoogle Scholar
  184. 184.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after Dl and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522–1530.PubMedCrossRefGoogle Scholar
  185. 185.
    Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418–425.PubMedCrossRefGoogle Scholar
  186. 186.
    Noguchi Y, Imada T, Matsumoto A, et al. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989;64:2053–2062.PubMedCrossRefGoogle Scholar
  187. 187.
    Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989;209:162–166.PubMedCrossRefGoogle Scholar
  188. 188.
    Svedlund J, Sullivan M, Liedman B, et al. Quality of life after gastrectomy for gastric carcinoma: controlled study of reconstructive procedures. World J Surg 1997;21:422–433.PubMedCrossRefGoogle Scholar
  189. 189.
    Chareton B, Landen S, Manganas D, et al. Prospective randomized trial comparing Billroth I and Billroth II procedures for carcinoma of the gastric antrum. J Am Coll Surg 1996;183:190–194.PubMedGoogle Scholar
  190. 190.
    Fuchs KH, Thiede A, Engemann R, et al. Reconstruction of the food passage after total gastrectomy: randomized trial. World J Surg 1995;19:698–705; discussion 705–706.PubMedCrossRefGoogle Scholar
  191. 191.
    Iivonen MK, Mattila JJ, Nordback IH, Matikainen MJ. Long-term follow-up of patients with jejunal pouch reconstruction after total gastrectomy. A randomized prospective study. Scand J Gastroenterol 2000;35:679–685.PubMedCrossRefGoogle Scholar
  192. 192.
    Nakane Y, Okumura S, Akehira K, et al. Jejunal pouch reconstruction after total gastrectomy for cancer. A randomized controlled trial. Ann Surg 1995;222:27–35.PubMedCrossRefGoogle Scholar
  193. 193.
    Espat NJ, Karpeh M. Reconstruction following total gastrectomy: a review and summary of the randomized prospective clinical trials. Surg Oncol 1998;7:65–69.PubMedCrossRefGoogle Scholar
  194. 194.
    Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113–1119.PubMedCrossRefGoogle Scholar
  195. 195.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.PubMedCrossRefGoogle Scholar
  196. 196.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.PubMedCrossRefGoogle Scholar
  197. 197.
    Brenner H, Arndt V, Sturmer T, et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000;88:274–279.PubMedCrossRefGoogle Scholar
  198. 198.
    La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer 1992;70:50–55.PubMedCrossRefGoogle Scholar
  199. 199.
    Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994;3:15–18.PubMedGoogle Scholar
  200. 200.
    Itzkowitz SH. Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:1133–1144.PubMedCrossRefGoogle Scholar
  201. 201.
    Oberhuber G, Stangl PC, Vogelsang H, et al. Significant association of strictures and internal fistula formation in Crohn’s disease. Virchows Arch 2000;437:293–297.PubMedCrossRefGoogle Scholar
  202. 202.
    Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992;102:1980–1982.PubMedGoogle Scholar
  203. 203.
    Burt RW. Gastric fundic gland polyps. Gastroenterology 2003;125:1462–1469.PubMedCrossRefGoogle Scholar
  204. 204.
    Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998;5:751–756.PubMedCrossRefGoogle Scholar
  205. 205.
    El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000;118:22–30.PubMedCrossRefGoogle Scholar
  206. 206.
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580.PubMedCrossRefGoogle Scholar
  207. 207.
    Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708–710.PubMedCrossRefGoogle Scholar
  208. 208.
    Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186:665–669.PubMedCrossRefGoogle Scholar
  209. 209.
    Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338–352.PubMedGoogle Scholar
  210. 210.
    Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168–172.PubMedCrossRefGoogle Scholar
  211. 211.
    Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol 2007;10:123–133.PubMedCrossRefGoogle Scholar
  212. 212.
    Fischbach W, Goebeler-Kolve ME, Dragosics B, et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34–37.PubMedCrossRefGoogle Scholar
  213. 213.
    Collins RH. Gastrointestinal lymphomas. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Vol. 1. Philadelphia: Saunders; 2006:565–587.Google Scholar
  214. 214.
    Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch 2000;437:581–590.PubMedCrossRefGoogle Scholar
  215. 215.
    Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. Am J Surg Pathol 2001;25:500–507.PubMedCrossRefGoogle Scholar
  216. 216.
    Stolte M. Clinical consequences of the endoscopic diagnosis of gastric polyps. Endoscopy 1995;27:32–37; discussion 59–60.PubMedCrossRefGoogle Scholar
  217. 217.
    Debongnie JC. Gastric polyps. Acta Gastroenterol Belg 1999;62:187–189.PubMedGoogle Scholar
  218. 218.
    Burke CA, van Stolk RU. Diagnosis and management of gastro-duodenal polyps. Surg Oncol Clin N Am 1996;5:589–607.PubMedGoogle Scholar
  219. 219.
    Stolte M, Sticht T, Eidt S, et al. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy 1994;26:659–665.PubMedCrossRefGoogle Scholar
  220. 220.
    Nakamura T, Nakano G. Histopathological classification and malignant change in gastric polyps. J Clin Pathol 1985;38:754–764.PubMedCrossRefGoogle Scholar
  221. 221.
    Graham DY, Schwartz JT. The spectrum of the Mallory-Weiss tear. Medicine (Baltimore) 1978;57:307–318.PubMedCrossRefGoogle Scholar
  222. 222.
    Peura DA, Lanza FL, Gostout CJ, Foutch PG. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 1997;92:924–928.PubMedGoogle Scholar
  223. 223.
    Wilcox CM, Clark WS. Causes and outcome of upper and lower gastrointestinal bleeding: the Grady Hospital experience. South Med J 1999;92:44–50.PubMedGoogle Scholar
  224. 224.
    Hixson SD, Burns RP, Britt LG. Mallory-Weiss syndrome: retrospective review of eight years’ experience. South Med J 1979;72:1249–1251.PubMedGoogle Scholar
  225. 225.
    Scharschmidt BF. The natural history of hypertrophic gastrophy (Menetrier’s disease). Report of a case with 16 year follow-up and review of 120 cases from the literature. Am J Med 1977;63:644–652.PubMedCrossRefGoogle Scholar
  226. 226.
    Burdick JS, Chung E, Tanner G, et al. Treatment of Menetrier’s disease with a monoclonal antibody against the epidermal growth factor receptor. N Engl J Med 2000;343:1697–1701.PubMedCrossRefGoogle Scholar
  227. 227.
    Komorowski RA, Caya JG. Hyperplastic gastropathy. Clinicopathologic correlation. Am J Surg Pathol 1991;15:577–585.PubMedCrossRefGoogle Scholar
  228. 228.
    Wolfsen HC, Carpenter HA, Talley NJ. Menetrier’s disease: a form of hypertrophic gastropathy or gastritis? Gastroenterology 1993;104:1310–1319.PubMedGoogle Scholar
  229. 229.
    Mulvihill SJ. Neoplasms of the stomach. In: Bell RH, Rikkers LF, Mulholland MW, eds. Digestive Tract Surgery: A Text and Atlas. Philadelphia: Lippincott-Raven; 1996:255–279.Google Scholar
  230. 230.
    Miko TL, Thomazy VA. The caliber persistent artery of the stomach: a unifying approach to gastric aneurysm, Dieulafoy’s lesion, and submucosal arterial malformation. Hum Pathol 1988;19:914–921.PubMedCrossRefGoogle Scholar
  231. 231.
    Norton ID, Petersen BT, Sorbi D, et al. Management and long-term prognosis of Dieulafoy lesion. Gastrointest Endosc 1999;50:762–767.PubMedCrossRefGoogle Scholar
  232. 232.
    McGrath K, Mergener K, Branch S. Endoscopic band ligation of Dieulafoy’s lesion: report of two cases and review of the literature. Am J Gastroenterol 1999;94:1087–1090.PubMedCrossRefGoogle Scholar
  233. 233.
    Chandrashekar L, Brown RD, Venu RP. Management of Dieulafoy’s lesion in the endoscopic era. J Clin Gastroenterol 2003;36:294–296.PubMedCrossRefGoogle Scholar
  234. 234.
    Kasapidis P, Georgopoulos P, Delis V, et al. Endoscopic management and long-term follow-up of Dieulafoy’s lesions in the upper GI tract. Gastrointest Endosc 2002;55:527–531.PubMedCrossRefGoogle Scholar
  235. 235.
    Mumtaz R, Shaukat M, Ramirez FC. Outcomes of endoscopic treatment of gastroduodenal Dieulafoy’s lesion with rubber band ligation and thermal/injection therapy. J Clin Gastroenterol 2003;36:310–314.PubMedCrossRefGoogle Scholar
  236. 236.
    Yamaguchi Y, Yamato T, Katsumi N, et al. Short-term and long-term benefits of endoscopic hemoclip application for Dieulafoy’s lesion in the upper GI tract. Gastrointest Endosc 2003;57:653–656.PubMedCrossRefGoogle Scholar
  237. 237.
    Pfau PR, Ginsberg G.G. Foreign Bodies and Bezoars. Vol. 1, 7th ed. Philadelphia: Saunders; 2002.Google Scholar
  238. 238.
    Escamilla C, Robles-Campos R, Parrilla-Paricio P, et al. Intestinal obstruction and bezoars. J Am Coll Surg 1994;179:285–288.PubMedGoogle Scholar
  239. 239.
    Sanderson I, Ibberson O, Fish EB. Gastric phytobezoar following gastrectomy. Can Med Assoc J 1971;104:1115 passim.PubMedGoogle Scholar
  240. 240.
    Andrus CH, Ponsky JL. Bezoars: classification, pathophysiology, and treatment. Am J Gastroenterol 1988;83:476–478.PubMedGoogle Scholar
  241. 241.
    Diettrich NA, Gau FC. Postgastrectomy phytobezoars—endoscopic diagnosis and treatment. Arch Surg 1985;120:432–435.PubMedGoogle Scholar
  242. 242.
    Phillips MR, Zaheer S, Drugas GT. Gastric trichobezoar: case report and literature review. Mayo Clin Proc 1998;73:653–656.PubMedCrossRefGoogle Scholar
  243. 243.
    Williams RS. The fascinating history of bezoars. Med J Aust 1986;145:613–614.PubMedGoogle Scholar
  244. 244.
    Yao CC, Wong HH, Chen CC, et al. Laparoscopic removal of large gastric phytobezoars. Surg Laparosc Endosc Percutan Tech 2000;10:243–245.PubMedCrossRefGoogle Scholar
  245. 245.
    Hopman WP, Wolberink RG, Lamers CB, Van Tongeren JH. Treatment of the dumping syndrome with the somatostatin analogue SMS 201–995. Ann Surg 1988;207:155–159.PubMedCrossRefGoogle Scholar
  246. 246.
    Tulassay Z, Tulassay T, Gupta R, Cierny G. Long-acting analogue of somatostatin—SMS 201–995—is highly effective in the prevention of clinical symptoms related to the dumping syndrome. Ann Surg 1989;210:250–252.PubMedGoogle Scholar
  247. 247.
    Primrose JN. Octreotide in the treatment of the dumping syndrome. Digestion 1990;45(suppl 1):49–58; discussion 58–59.PubMedCrossRefGoogle Scholar
  248. 248.
    Geer RJ, Richards WO, O’Dorisio TM, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg 1990;212:678–687.PubMedCrossRefGoogle Scholar
  249. 249.
    Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg 1991;126:1231–1235; discussion 1235–1236.PubMedGoogle Scholar
  250. 250.
    Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996;277:1359–1365.PubMedGoogle Scholar
  251. 251.
    Ishikawa M, Kitayama J, Kaizaki S, et al. Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma. World J Surg 2005;29:1415–1420; discussion 1421.PubMedCrossRefGoogle Scholar
  252. 252.
    Debas HT. Stomach and duodenum. In: Gastrointestinal Surgery. New York: Springer; 2004.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Robert E. Glasgow
    • 1
  • Michael D. Rollins
    • 1
  1. 1.Department of SurgeryUniversity of UtahSalt Lake CityUSA

Personalised recommendations